دورية أكاديمية
أعرض في EDS

HOXA1 3'UTR Methylation Is a Potential Prognostic Biomarker in Oral Squamous cell Carcinoma.

التفاصيل البيبلوغرافية
العنوان: HOXA1 3'UTR Methylation Is a Potential Prognostic Biomarker in Oral Squamous cell Carcinoma.
المؤلفون: Sorroche BP; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., Miranda KC; Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos 12224-300, Brazil., Beltrami CM; International Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil., Arantes LMRB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., Kowalski LP; Head and Neck Surgery and Otorhinolaryngology Department, AC Camargo Cancer Center, Latin American Cooperative Oncology Group, São Paulo 01509-010, Brazil.; Head and Neck Surgery Department and LIM 28, University of São Paulo Medical School, São Paulo 01246-903, Brazil., Marchi FA; Center for Translational Research in Oncology, Cancer Institute of the State of São Paulo (ICESP), São Paulo 01246-000, Brazil.; Clinical Hospital of the University of Sao Paulo Medical School (HCFMUSP), São Paulo 05403-010, Brazil., Rogatto SR; Department of Clinical Genetics, University Hospital of Southern Denmark, 7100 Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark., Almeida JD; Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos 12224-300, Brazil.
المصدر: Cancers [Cancers (Basel)] 2024 Feb 22; Vol. 16 (5). Date of Electronic Publication: 2024 Feb 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: HOXA1 is a prognostic marker and a potential predictive biomarker for radioresistance in head and neck tumors. Its overexpression has been associated with promoter methylation and a worse prognosis in oral squamous cell carcinoma (OSCC) patients. However, opposite outcomes are also described. The effect of the methylation of this gene on different gene regions, other than the promoter, remains uncertain. We investigated the methylation profile at different genomic regions of HOXA1 in OSCC and correlated differentially methylated CpG sites with clinicopathological data.
Methods: The HOXA1 DNA methylation status was evaluated by analyzing data from The Cancer Genome Atlas and three Gene Expression Omnibus datasets. Significant differentially methylated CpG sites were considered with a |∆β| ≥ 0.10 and a Bonferroni-corrected p -value < 0.01. Differentially methylated CpGs were validated by pyrosequencing using two independent cohorts of 15 and 47 OSCC patients, respectively.
Results: Compared to normal tissues, we found significantly higher DNA methylation levels in the 3'UTR region of HOXA1 in OSCC. Higher methylation levels in tumor samples were positively correlated with smoking habits and patients' overall survival.
Conclusions: Our findings suggest that HOXA1 gene body methylation is a promising prognostic biomarker for OSCC with potential clinical applications in patient monitoring.
References: J Oral Pathol Med. 2024 Feb;53(2):90-106. (PMID: 38316046)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
BMC Cancer. 2012 Apr 12;12:146. (PMID: 22498108)
BMC Cancer. 2019 May 17;19(1):467. (PMID: 31101023)
Auris Nasus Larynx. 2019 Feb;46(1):10-17. (PMID: 30172560)
Nat Rev Genet. 2012 May 29;13(7):484-92. (PMID: 22641018)
Head Neck. 2009 Nov;31(11):1423-30. (PMID: 19431196)
Genes Dis. 2018 Jan 31;5(1):1-8. (PMID: 30258928)
Eur J Cancer. 2023 Jan;178:91-113. (PMID: 36427394)
Oncotarget. 2015 Jan 20;6(2):915-34. (PMID: 25460508)
Science. 1990 Sep 14;249(4974):1288-90. (PMID: 1697983)
Mol Cancer Res. 2016 Sep;14(9):805-19. (PMID: 27288358)
Oral Oncol. 2011 Aug;47(8):702-8. (PMID: 21697000)
Oral Oncol. 2009 Dec;45(12):1051-7. (PMID: 19665921)
EBioMedicine. 2019 May;43:127-137. (PMID: 31056473)
N Engl J Med. 2020 Jan 2;382(1):60-72. (PMID: 31893516)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cytopathology. 2016 Apr;27(2):122-30. (PMID: 25988212)
Science. 2016 Nov 4;354(6312):618-622. (PMID: 27811275)
EMBO J. 2017 Jun 1;36(11):1471-1473. (PMID: 28442531)
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5968-77. (PMID: 25337241)
Cancers (Basel). 2021 Jun 11;13(12):. (PMID: 34207933)
Hum Mol Genet. 2009 Apr 1;18(7):1332-42. (PMID: 19153073)
Trends Genet. 2014 Feb;30(2):75-84. (PMID: 24368016)
Arch Oral Biol. 2019 Feb;98:265-272. (PMID: 30576962)
Nucleic Acids Res. 2017 Jan 25;45(2):583-596. (PMID: 27899617)
Annu Rev Pathol. 2022 Jan 24;17:295-321. (PMID: 34736341)
Clin Epigenetics. 2022 Nov 28;14(1):154. (PMID: 36443876)
Genome Med. 2015 Oct 24;7:108. (PMID: 26497652)
Epigenetics. 2016 Sep;11(9):643-652. (PMID: 27245195)
Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310)
Nat Commun. 2017 Oct 20;8(1):1077. (PMID: 29057876)
Int J Oral Maxillofac Surg. 2018 Aug;47(8):976-982. (PMID: 29449053)
Nucleic Acids Res. 2016 May 5;44(8):e71. (PMID: 26704973)
Genes Dev. 2003 Feb 15;17(4):419-37. (PMID: 12600935)
Nat Genet. 2005 Oct;37(10):1035-7. (PMID: 16155570)
Oral Oncol. 2013 Nov;49(11):1033-42. (PMID: 24035722)
Clin Epigenetics. 2017 Feb 3;9:13. (PMID: 28174608)
Eur J Cancer. 2014 May;50(8):1541-54. (PMID: 24559685)
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7526-E7535. (PMID: 28827334)
Genomics. 2018 Mar;110(2):112-123. (PMID: 28890207)
Front Mol Biosci. 2021 Mar 08;7:602068. (PMID: 33763449)
Front Immunol. 2018 Mar 12;9:473. (PMID: 29662483)
Technol Cancer Res Treat. 2017 Dec;16(6):1252-1258. (PMID: 29484968)
Oncol Rev. 2014 Jun 30;8(1):244. (PMID: 25992232)
Adv Clin Exp Med. 2018 Jun;27(6):833-840. (PMID: 29790687)
Br J Oral Maxillofac Surg. 2007 Dec;45(8):617-22. (PMID: 17559992)
BMC Genomics. 2013 May 01;14:293. (PMID: 23631413)
Arch Oral Biol. 2019 Mar;99:92-106. (PMID: 30641296)
Indian J Surg Oncol. 2022 Jun;13(2):267-280. (PMID: 35782825)
Med Oncol. 2013;30(3):654. (PMID: 23824644)
Oncol Rep. 2015 Nov;34(5):2636-42. (PMID: 26352791)
Arch Oral Biol. 2022 Nov;143:105544. (PMID: 36126567)
Ann Surg Oncol. 2014 Sep;21(9):3124-31. (PMID: 24671639)
معلومات مُعتمدة: 2016/08633-0 Fundação de Amparo à Pesquisa do Estado de São Paulo
فهرسة مساهمة: Keywords: DNA methylation; HOXA1; head and neck cancer; oral squamous cell carcinoma; tumor suppressor gene
تواريخ الأحداث: Date Created: 20240313 Latest Revision: 20240315
رمز التحديث: 20240315
مُعرف محوري في PubMed: PMC10930908
DOI: 10.3390/cancers16050874
PMID: 38473236
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16050874